Circulating Small Extracellular Vesicles Profiling and Thrombin Generation as Potential Markers of Thrombotic Risk in Glioma Patients.

Autor:	Melnichnikova O; Personalized Medicine Centre, Almazov National Medical Research Centre, Saint Petersburg, Russia., Zhilenkova Y; Department of Laboratory Medicine and Genetics, Almazov National Medical Research Centre, Saint Petersburg, Russia., Sirotkina O; Personalized Medicine Centre, Almazov National Medical Research Centre, Saint Petersburg, Russia., Zolotova E; Personalized Medicine Centre, Almazov National Medical Research Centre, Saint Petersburg, Russia., Pishchulov K; Personalized Medicine Centre, Almazov National Medical Research Centre, Saint Petersburg, Russia., Tastanbekov M; Department of Neurosurgery, Almazov National Medical Research Centre, Saint Petersburg, Russia., Paltsev A; Department of Neurosurgery, Almazov National Medical Research Centre, Saint Petersburg, Russia., Simakova M; Personalized Medicine Centre, Almazov National Medical Research Centre, Saint Petersburg, Russia.
Jazyk:	angličtina
Zdroj:	Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2022 Jun 23; Vol. 9, pp. 789937. Date of Electronic Publication: 2022 Jun 23 (Print Publication: 2022).
DOI:	10.3389/fcvm.2022.789937
Abstrakt:	Introduction: Patients with glioma (GM) are at a high risk of venous thromboembolism (VTE). The role of microvesiculation in the cancer-associated thrombosis mechanisms has been previously demonstrated. This study aimed to evaluate the relative abundance of extracellular vesicles (EVs) and thrombin generation (TG) in combination with standard laboratory tests in patients with newly diagnosed GM as potential prognostic markers in VTE. Materials and Methods: In the present study, 11 patients with newly diagnosed GM and 10 healthy volunteers were analyzed. EVs were counted and their cellular origin was determined (CytoFlex B4-R2-V2, Beckman Coulter, United States), as well as thrombin generation test (TGT) (Diagnostica Stago SAS, France) was performed. Results: In patients with GM, the relative abundance of the CD41 + EVs (platelet-derived)-and CD105 + EVs (endothelial-derived) was significantly higher than in the control group (44.3 [40.5; 52.4] vs. 27.2 [22.9; 31.0]%, p = 0.002, and 5.4 [4.8; 7.8] vs. 1.9 [1.5; 2.8]%, p = 0.0003, respectively). The D-dimer level was higher in patients with GM compared with the control group (0.46 [0.38; 1.85] vs. 0.36 [0.27; 0.40] μg/ml FEU, p = 0.03, respectively). There was a trend toward an increase in the peak thrombin and velocity index (VI) in the GM group ( p = 0.06). During the follow-up period, two patients (18%) developed thrombosis, had tumor sizes of more than 5 cm, thrombocytopenia, increased VI, and D-dimer. Conclusion: Analysis of platelet-derived EVs, platelet count, and TGT in combination with D-dimer assessment could improve the stratification of patients prone to VTE, which needs to be confirmed in a larger sample. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Melnichnikova, Zhilenkova, Sirotkina, Zolotova, Pishchulov, Tastanbekov, Paltsev and Simakova.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu